Associated Papers
Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer.
Chaubal R et al.
Breast Cancer Research and Treatment, 2025
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer.
Börcsök J et al.
The Journal of Clinical Investigation, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
Thorvaldsdottir B et al.
Leukemia, 2025
Precision proteogenomics reveals pan-cancer impact of germline variants.
Martins Rodrigues F et al.
Cell, 2025
Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression.
Landsburg DJ et al.
Cancer Research Communications, 2024
Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.
Pantaleo A et al.
Cancers, 2023
Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer.
Serebriiskii IG et al.
Npj Genomic Medicine, 2023
Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.
Badar T et al.
Haematologica, 2023
DDX41 mutations in patients with non-myeloid hematologic neoplasms.
Jelloul FZ et al.
American Journal of Hematology, 2023
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y et al.
Blood Advances, 2023
Clinicopathological and molecular characteristics of patients with hypermutant lung cancer: A retrospective cohort study.
Zhang H et al.
Oncology Letters, 2021
Comprehensive genomic profile of cholangiocarcinomas in China.
Tian W et al.
Oncology Letters, 2020
Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon.
Baniak N et al.
The American Journal of Surgical Pathology, 2019
Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO et al.
Nature Genetics, 2018
Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer.
Ashktorab H et al.
Oncotarget, 2017
Germ-line and somatic EPHA2 coding variants in lens aging and cataract.
Bennett TM et al.
Plos One, 2017
The Czech National Diamond-Blackfan Anemia Registry: clinical data and ribosomal protein mutations update.
Pospisilova D et al.
Blood Cells, Molecules & Diseases, 2012
Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma.
Mahaffey CM et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2012
Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.
Santos R et al.
Antioxidants & Redox Signaling, 2010
Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing.
Besaratinia A et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2010
Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells.
Besaratinia A et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2008
Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study.
Fouquet C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2004
Spontaneous mutation in Big Blue mice from fetus to old age: tissue-specific time courses of mutation frequency but similar mutation types.
Hill KA et al.
Environmental and Molecular Mutagenesis, 2004
Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
Edamoto Y et al.
International Journal of Cancer, 2003
Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations.
Medina PP et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2003
Prognostic value of P53 mutations in rectal carcinoma.
Rebischung C et al.
International Journal of Cancer, 2002
Discordance of genetic alterations between primary head and neck tumors and corresponding metastases associated with mutational status of the TP53 gene.
Tabor MP et al.
Genes, Chromosomes & Cancer, 2002
p53 as a mutagen test in breast cancer.
Hill KA et al.
Environmental and Molecular Mutagenesis, 2002
Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors.
Lothe RA et al.
Genes, Chromosomes & Cancer, 2001
Gene- and tissue-specificity of mutation in Big Blue rats treated with the hepatocarcinogen N-hydroxy-2-acetylaminofluorene.
Chen T et al.
Environmental and Molecular Mutagenesis, 2001
p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma.
King TC et al.
Cancer, 2000
P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.
Katiyar S et al.
Cancer, 2000
Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India.
Ralhan R et al.
International Journal of Cancer, 2000
Analysis of the p53 tumor suppressor gene in rheumatoid arthritis synovial fibroblasts.
Kullmann F et al.
Arthritis and Rheumatism, 1999
Patterns of genetic alterations in pancreatic cancer: a pooled analysis.
Blanck HM et al.
Environmental and Molecular Mutagenesis, 1999
Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use.
Xu J et al.
Cancer, 1998
Discrimination of DNA binding sites by mutant p53 proteins.
Thukral SK et al.
Molecular and Cellular Biology, 1995